Dynamic Advisor Solutions LLC Decreases Stock Holdings in Sanofi $SNY

Dynamic Advisor Solutions LLC reduced its stake in shares of Sanofi (NASDAQ:SNY) by 87.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,290 shares of the company’s stock after selling 52,401 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Sanofi were worth $353,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock valued at $1,693,000 after buying an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after buying an additional 752 shares during the last quarter. Sivia Capital Partners LLC raised its stake in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after buying an additional 347 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in shares of Sanofi in the 2nd quarter worth about $1,178,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SNY shares. Citigroup started coverage on shares of Sanofi in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, TD Cowen restated a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $61.50.

Sanofi Price Performance

NASDAQ:SNY opened at $46.78 on Friday. Sanofi has a 12-month low of $43.32 and a 12-month high of $55.99. The firm has a market cap of $114.10 billion, a price-to-earnings ratio of 12.99, a price-to-earnings-growth ratio of 1.16 and a beta of 0.45. The company’s 50-day moving average is $46.31 and its two-hundred day moving average is $47.99. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.